Abstract:The coronavirus disease 2019 (COVID-19) pandemic has affected health and economy worldwide on an unprecedented scale. Patients have diverse clinical outcomes, but those with preexisting cardiovascular disease, hypertension, and related conditions incur disproportionately worse outcome. The high infectivity of severe acute respiratory syndrome coronavirus 2 is in part related to new mutations in the receptor binding domain, and acquisition of a furin cleavage site in the S-spike protein. The continued viral shedding in the asymptomatic and presymptomatic individuals enhances its community transmission. The virus uses the angiotensin converting enzyme 2 receptor for internalization, aided by transmembrane protease serine 2 protease. The tissue localization of the receptors correlates with COVID-19 presenting symptoms and organ dysfunction. Virus-induced angiotensin converting enzyme 2 downregulation may attenuate its function, diminish its anti-inflammatory role, and heighten angiotensin II effects in the predisposed patients. Lymphopenia occurs early and is prognostic, potentially associated with reduction of the CD4+ and some CD8+ T cells. This leads to imbalance of the innate/acquired immune response, delayed viral clearance, and hyperstimulated macrophages and neutrophils. Appropriate type I interferon pathway activation is critical for virus attenuation and balanced immune response. Persistent immune activation in predisposed patients, such as elderly adults and those with cardiovascular risk, can lead to hemophagocytosis-like syndrome, with uncontrolled amplification of cytokine production, leading to multiorgan failure and death. In addition to the airways and lungs, the cardiovascular system is often involved in COVID-19 early, reflected in the release of highly sensitive troponin and natriuretic peptides, which are all extremely prognostic, in particular, in those showing continued rise, along with cytokines such as interleukin-6. Inflammation in the vascular system can result in diffuse microangiopathy with thrombosis. Inflammation in the myocardium can result in myocarditis, heart failure, cardiac arrhythmias, acute coronary syndrome, rapid deterioration, and sudden death. Aggressive support based on early prognostic indicators with expectant management can potentially improve recovery. Appropriate treatment for heart failure, arrhythmias, acute coronary syndrome, and thrombosis remain important. Specific evidence-based treatment strategies for COVID-19 will emerge with ongoing global collaboration on multiple approaches being evaluated. To protect the wider population, antibody testing and effective vaccine will be needed to make COVID-19 history.

Scientific Statement of the Chinese Society of Cardiology (CSC) on Using of Renin Angiotensin System Blockers in Patients with Cardiovascular Disease and COVID-19.

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic

2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases

Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension

Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review

Association Of Acei/Arb Use And Clinical Outcomes Of Covid-19 Patients With Hypertension

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options

Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality

Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities

Counter-regulatory renin-angiotensin system in hypertension: review and update in the era of COVID-19 pandemic

Hypertension as a sequela in patients of SARS-CoV-2 infection

COVID-19 and the cardiovascular system

SARS-CoV-2 and Cardiovascular Complications: from Molecular Mechanisms to Pharmaceutical Management

Crosstalk Between Coronavirus Disease 2019 and Cardiovascular Disease and Its Treatment

Cardiovascular risk and complications associated with COVID-19

The Science Underlying COVID-19: Implications for the Cardiovascular System

Renin–Angiotensin System Blocker in COVID-19. A Single Center Study.

COVID-19 and the cardiovascular system: a study of pathophysiology and interpopulation variability

Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19

Cardiovascular Changes in Patients With COVID-19 From Wuhan, China

The role of cardiovascular system in the SARS-CoV-2 infection and aggravation in human